Rheumatoid Arthritis News and Research

Latest Rheumatoid Arthritis News and Research

New treatment for dry eye syndrome (keratoconjunctivitis sicca)

Researchers in the department of ophthalmology at the University of Arizona College of Medicine in Tucson played an important role in the development of Restasis, the first alternative to artificial tears for the treatment of dry eye syndrome.

21 May 2004

Study comparing the efficacy of REMICADE® to Azathioprine alone and in combination With REMICADE®

Centocor, Inc., and Schering-Plough Corporation announced today the initiation of the SONIC (Study of Immunomodulator Naive patients in Crohn's Disease) trial that will evaluate the efficacy of REMICADE® (infliximab) versus azathioprine, a conventional immunosuppressive agent, alone and versus the combination of both drugs for the treatment of patients with Crohn's disease.

18 May 2004

Facts about prevalence of arthritis in the U.S.A

Arthritis is the leading cause of physical disability in the United States. Arthritis comprises over 100 different disease and conditions. The most common are osteoarthritis, rheumatoid arthritis, fibromyalgia, and gout.

15 May 2004

Immtech signs agreement with CombinatoRx to test Immtech compounds as potential cancer treatment

Immtech International, Inc. announced today that it signed an agreement with CombinatoRx of Boston, Massachusetts to screen its lead aromatic cationic compounds, DB289 and DB75, for activity against various cancers.

5 May 2004

Study identifies key factor causing low iron and anemia in patients with infections and major inflammatory diseases

UCLA researchers found that a member of the immune system’s defense team stimulates a chain reaction leading to chronic anemia in many patients with infections and major inflammatory diseases.

3 May 2004

Psoriasis medications can treat more than the skin

The National Psoriasis Foundation, Dermatology Nurses Association, Dermatologists and People with Psoriasis have collaborated to offer a new resource to help people with psoriasis cope with the social and emotional impact of psoriasis.

27 Apr 2004

A new study is better defining the impact that stress and depression have on women suffering from rheumatoid arthritis

A new study is better defining the impact that stress and depression have on women suffering from rheumatoid arthritis (RA). The research, led by a team of ASU psychologists, shows increased pain and inflammation for those dealing with high amounts of stress and depression.

26 Apr 2004

Fish oil reduces heart attack and blood vessel disease

Fish oil can help reduce deaths from heart disease, according to new evidence reports announced today by the Agency for Healthcare Research and Quality.

22 Apr 2004

500,000 patients have now been treated with REMICADE® worldwide

Centocor, Inc., announced today that more than a half million patients worldwide have now been treated with the anti-TNF agent REMICADE® (infliximab) since it was introduced in the United States five years ago.

21 Apr 2004

A promising new therapy for rheumatoid arthritis

A promising new therapy for rheumatoid arthritis (RA) developed by researchers at the University of California, San Diego (UCSD) School of Medicine re-educates the body's immune system to prevent an attack against healthy joint tissue.

21 Apr 2004

New research findings about T-cell transport shed light on immune system

New research findings about T-cell transport shed light on how the normal immune system functions and could have implications in fighting autoimmune and inflammatory diseases, say researchers at University of Texas Southwestern Medical Center, Dallas.

20 Apr 2004

Bad hygiene may be good for you

A group of scientists at The Scripps Research Institute have found a connection between poor T cell survival in the body and the development of autoimmunity.

16 Apr 2004

Researchers have developed a new method for finding antigens

Researchers at National Jewish Medical and Research Center have developed a method for finding the molecular targets of the immune system, known as antigens.

13 Apr 2004

Coronary stent drives Johnson & Johnson to record profits

Johnson & Johnson today announced sales for the first quarter of $11.6 billion, an increase of 17.7% over the prior year. The increase represented operational growth of 12.3% and a currency impact of 5.4%. Domestic sales were up 15.1%, while international sales increased 21.8%, including operational growth of 7.8% and a positive currency impact of 14.0%.

13 Apr 2004

FDA accepts REMICADE® (infliximab) for the treatment of early rheumatoid arthritis

Centocor, Inc., announced today that the U.S. Food and Drug Administration (FDA) has accepted its filing of a supplemental Biologics License Application (sBLA) for REMICADE® (infliximab) as first-line therapy, in combination with methotrexate, for the treatment of early rheumatoid arthritis (RA) patients with moderately-to-severely active disease. REMICADE®, in combination with methotrexate, is currently indicated in the U.S. for reducing signs and symptoms, inhibiting the progression of structural damage and improving physical function in patients with moderately-to-severely active RA who have had an inadequate response to methotrexate alone.

6 Apr 2004

How rat's genetic blueprint stacks up against those of mice and humans

An international research team, supported by the National Institutes of Health (NIH), today announced it has completed a high-quality, draft sequence of the genome of the laboratory rat, and has used that data to explore how the rat's genetic blueprint stacks up against those of mice and humans.

31 Mar 2004

New patent to develop antibody therapies for cancer and other diseases

The University of Rochester Medical Center and Vaccinex, Inc. announced today the award of a key U.S. patent for a technology platform that can assist researchers in finding new treatments for cancer and other diseases. While the technology has many applications, one promising use is for the identification of certain proteins, called monoclonal antibodies, that are capable of seeking out and destroying harmful cells. Several companies have recently developed monoclonal antibodies as treatments for cancer, rheumatoid arthritis, and other conditions. Under an exclusive, worldwide license from the University of Rochester, Vaccinex is using the patented technology to discover and develop new monoclonal antibody therapies.

26 Mar 2004

A common antibiotic used to treat arthritis and acne shows promise for limiting the severity of spinal cord and brain injuries

When a fall, car crash, bullet, or knife crushes or cuts a spinal cord, the injury does not stop there. Rather, tissues continue to discharge toxic chemicals for hours, even days and weeks. These chemicals kill and disable nerve cells some distance away from the core injury, compounding the damage and making rehabilitation more difficult or impossible.

26 Mar 2004

Thyroid disorders are often misdiagnosed

Thyroid disorders are among the most common medical conditions. However, because their symptoms often appear gradually, the condition is often misdiagnosed, according to Dr. Nila Vora, a board-certified endocrinologist at the Loyola Primary Care Center in Darien.

25 Mar 2004

Lupus Discovery May Lead To Improved Drugs

In an important development in the treatment of lupus as well as certain cancers, scientists at the Feinberg School of Medicine at Northwestern University have discovered how autoimmune lupus T cells stave off programmed cell death and drive production of autoantibodies directed against the body’s own DNA.

22 Mar 2004